Walgreens teams up with Verily to tackle chronic conditions

Amy Baxter | | Health Exec | Precision Medicine

Walgreens Boots Alliance has teamed up with Verily, the life sciences unit of Google parent company Alphabet. The two companies will focus on improving outcomes for patients with chronic conditions, CNBC reported.

The partnership will deploy Verily’s technology at Walgreens’ pharmacies and specifically focus on medication adherence, an issue that costs the healthcare system about $100 billion to $289 billion annually.

The partnership may help Walgreens connect more technology to its growing healthcare services and could signal a move to fend off competitors like CVS Health, which recently acquired health insurance provider Aetna, and Amazon, which has continued to step into the pharmacy and healthcare space.

See the full story below:

Walgreens to tackle health-care costs with Alphabet’s Verily

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA commissioner urges clinicians to join fight against medical misinformation

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."
 

AI in Healthcare
4 points crucial to the nimble regulation of GenAI

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup